Heska Corporation Announces Board Action
Heska Corporation Announces Board Action
LOVELAND, Colo., May 2, 2018 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"), a provider of advanced veterinary diagnostic and specialty products, announced that as part of the Company's ongoing efforts, the Board of Directors (the "Board") of Heska Corporation ("Heska") unanimously voted that the Board would remove Section 5.7 from the Amended and Restated 1997 Stock Incentive Plan (the "Stock Plan") should the Stock Plan be approved at Heska's 2018 Annual Meeting of Stockholders.
About Heska
Heska Corporation (NASDAQ: HSKA) manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products. Heska's business is composed of Core Companion Animal Health ("CCA") (81%) and Other Vaccines, Pharmaceuticals and Products ("OVP") (19%). CCA includes, primarily for canine and feline use, point of care laboratory testing instruments and supplies under a unique multi-year Reset Subscription model, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products. OVP includes, primarily for herd animal health, private label vaccine and pharmaceutical production under third party agreements and channels. For further information on Heska and its products, visit www.heska.com.
Forward-Looking Statements
This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes, including financial results and perceived customer behavior. Factors that could affect the business and financial results of Heska generally include, but are not limited to, the following: risks related to reliance on fourth parties to develop and manufacture products for Heska; risks related to the commercialization of new products; uncertainties related to attempts to expand into international markets, including, but not limited to, uncertainties related to timing, profitability and currency effects; uncertainties related to Heska's ability to measure and predict trends in the veterinary market; uncertainties related to Heska's ability to measure and predict the effectiveness of commercial relationships; uncertainties related to the future impact of recent business development activity; risks related to Heska's reliance on outside suppliers, which is substantial; competition; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-K for the period ended December 31, 2017.
CONTACT: Heska Corporation, Jon Aagaard, Director, Investor Relations, 970.619.3033, investorrelations@heska.com; or Hayden IR, Brett Maas, Managing Partner, 646.536.7331, brett@haydenir.com
View original content:http://www.prnewswire.com/news-releases/heska-corporation-announces-board-action-300641439.html
SOURCE Heska Corporation
